8-K current report · filed Nov 12, 2026

Taysha Gene Therapies, Inc. (TSHA) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1TSHA overview

Short answer

Taysha Gene Therapies, Inc. (TSHA) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 results for quarter ended September 30, 2026, covering financial performance and recent business highlights.

Taysha Gene Therapies, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 results for quarter ended September 30, 2026, covering financial performance and recent business highlights
  • Investor focus: Exhibit 99.1 contains the detailed results and company updates

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $39.1M, or $0.10 per share, versus $32.7M, or $0.09, increasing funding needs
  • Cash and equivalents $422.8M, supporting planned operations into the second half of 2028
  • TSHA-102 trials enrolled 33 patients with no severe treatment-related SAEs or DLTs as of November 2026
  • BLA-enabling PPQ campaign met product specifications and comparability criteria, strengthening commercial manufacturing readiness
  • REVEAL six-month interim data and FDA BLA pathway feedback expected in the first half of 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Taysha Gene Therapies, Inc. 8-K filings

Get the next TSHA 8-K as it lands

Follow TSHA for push alerts, or ask the research agent what this filing means.